癌症研究
化学
活性氧
免疫原性细胞死亡
卡巴齐塔塞尔
CD8型
癌症
癌症免疫疗法
免疫系统
药理学
免疫疗法
医学
免疫学
前列腺癌
内科学
生物化学
雄激素剥夺疗法
作者
Jiaoying Wang,Jie Li,Yao Wu,Xiaoxuan Xu,Xindi Qian,Ying Duan Lei,Huanzhen Liu,Zhiwen Zhang,Yaping Li
出处
期刊:Nano Letters
[American Chemical Society]
日期:2022-10-13
卷期号:22 (20): 8312-8320
被引量:9
标识
DOI:10.1021/acs.nanolett.2c03227
摘要
Despite the promising benefits of immune checkpoint inhibitors (ICIs) in clinical cancer treatments, the therapeutic efficacy is largely restricted by low antitumor immunity and limited intratumor delivery in solid tumors. Herein, we designed a reactive oxygen species (ROS)-responsive albumin nanocomplex of antiprogrammed cell death receptor ligand 1 (aPD-L1) and cabazitaxel (RAN-PC), which exhibited prominent tumor accumulation and intratumor permeation in 4T1 tumors. Compared with the negative control, the RAN-PC + radiation treatment (RAN-PC+X) produced a 3.61- and 5.10-fold enhancement in CD3+CD8+ T cells and the interferon (IFN)-γ-expressing subtype, respectively, and notably reduced versatile immunosuppressive cells. Moreover, RAN-PC+X treatment resulted in notable retardation of tumor growth, with a 78.97% inhibition in a 4T1 breast tumor model and a 90.30% suppression in a CT-26 colon tumor model. Therefore, the ROS-responsive albumin nanocomplex offers an encouraging platform for ICIs with prominent intratumor delivery capacity for cancer immunotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI